Trials / Active Not Recruiting
Active Not RecruitingNCT04388605
Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic
Assessing the Safety of Pregnancy In the CoRonavirus pandEmic: a Nationwide Prospective Study
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 7,965 (actual)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Prospective nationwide cohort study of pregnant women enrolled early in gestation and followed for Covid-19 exposure and infection, with follow up of obstetrical outcomes and infant development through the first year of life.
Detailed description
ASPIRE is focused on the first trimester, a critical and vulnerable period when all of a baby's organ systems form and the placenta - the crucial connection between mom and baby - develops. Currently, there are no data about the effects of COVID-19 infections in the first trimester. The study will provide critical information to: 1. Guide the care of pregnant women 2. Protect the safety of their babies and families 3. Help those considering pregnancy in the future understand what it means to be pregnant in this new era The investigators are recruiting 10,000 women from the start of pregnancy and will track COVID-19 exposures using frequent serology testing. The investigators will collect information during and after the pregnancy to try to determine the effects of COVID 19 for mom and baby. Participants will be asked to do the following throughout pregnancy: * Submit frequent, quick (\<1 minute each) symptom tracking reports using your mobile phone and/or computer. * Collect finger-stick blood samples from home at several points throughout your pregnancy. * Give permission to review medical records related to your pregnancy, delivery and baby's development. * Complete questionnaires online about your health during your pregnancy and after delivery of your baby.
Conditions
Timeline
- Start date
- 2020-04-21
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2020-05-14
- Last updated
- 2025-05-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04388605. Inclusion in this directory is not an endorsement.